根据左心室喷射分数的基础上,宁- ангиотензин系统抑制剂和非ST升高心肌梗塞结果
Yong Hoon Kim1, Ae-Young Her1, Seung-Woon Rha2
1Division of Cardiology, Department of Internal Medicine, Kangwon National University College of Medicine, Kangwon National University School of Medicine, Chuncheon 24289, Republic of Korea.
概括
在非ST段升高心肌梗塞 (NSTEMI) 患者中使用宁-血管酶系统抑制剂 (RASI) 与更好的结果有关,特别是在心力衰竭与保留射出小部分 (HFpEF) 中. 在LVEF亚组中,RASI使用显示改善了面向患者的综合结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非ST段升高心肌梗塞 (NSTEMI) 是一种严重的心血管疾病.
- 左心室喷射率 (LVEF) 是心脏功能的一个关键指标.
- 氨酶系统抑制剂 (RASI) 常用于心血管疾病管理.
研究的目的:
- 根据LVEF,比较RASI对NSTEMI患者的影响.
- 评估RASI对NSTEMI患者患者面向患者的综合结果 (POCO) 的影响.
- 分析与RASI在不同心力衰竭表型中的使用相关的死亡率和住院风险.
主要方法:
- 一组4558名NSTEMI患者被划分为RASI用户 (3752) 和非用户 (806).
- 主要结局是为期3年的POCO,包括全因死亡,复发性心脏病发作,再血管化或心力衰竭住院治疗.
- 计算了多变量调整的危险比率 (aHR),以比较临床结果.
主要成果:
- 与非使用者相比,RASI使用者在所有LVEF子组 (HFrEF,HFmrEF,HFpEF) 中始终显示POCO和全因死亡的调整后危险比率较低.
- 在RASI使用者中,POCO,全因死亡和心脏死亡的调整后危险比率在HFrEF中最高,在HFmrEF中中间,在HFpEF中最低.
- 在RASI非用户中观察到类似的趋势,与HFpEF相比,HFrEF和HFmrEF的风险更高.
结论:
- 使用RASI与改善面向患者的综合结局和减少不同LVEF的NSTEMI患者的死亡率有关.
- 拉西治疗的益处在心力衰竭患者中显得最明显,心力衰竭患者具有保存的喷射分数 (HFpEF).
- 基于LVEF的风险分层在考虑在NSTEMI管理中RASI治疗时至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:25Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
541
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
541
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324